Aesthetic medical device segment accounted for 66% of total sales (filler 30%, needles 31%), traditional Korean medicine segment 34%
Very low net debt-to-equity ratio of 0.53%, cash and cash equivalents KRW 262B
Credit rating: BB0 (downgraded from BBB- in 2024 by NICE), classified as SME and venture company
Ongoing patent infringement litigation (Seoul Central District Court, appeal after losing first instance, claim amount KRW 100M; company expects limited impact) and provision of KRW 880M for another lawsuit
R&D expenses KRW 3.5B (1.1% of sales), 50 patents and 23 overseas patents held